Pharmacodynamic effects during the transition between cangrelor and ticagrelor

Area of Science:

• Cardiology
• Pharmacology
• Thrombosis

Background:

• Cangrelor is an intravenous P2Y12 antagonist requiring transition to oral agents.
• Understanding these transitions is crucial for managing patients on antiplatelet therapy.

Purpose of the Study:

• To evaluate the pharmacodynamic effects during transitions between intravenous cangrelor and oral ticagrelor.
• To assess the impact of ticagrelor administration timing relative to cangrelor infusion.

Main Methods:

• 12 patients with stable coronary artery disease received cangrelor infusion and ticagrelor doses.
• Pharmacodynamic effects were measured using platelet aggregation assays and flow cytometry.
• Assessments were performed during and after cangrelor infusion, and during a subsequent cangrelor infusion.

Main Results:

• Cangrelor infusion led to significant platelet function inhibition.
• Ticagrelor's antiplatelet effects were preserved when administered during or after cangrelor.
• Platelet reactivity showed a modest increase after cangrelor cessation but remained controlled.

Conclusions:

• Ticagrelor can be administered before, during, or after cangrelor infusion without compromising its pharmacodynamic effects.
• The reversible binding of ticagrelor supports its flexible use in conjunction with cangrelor.
• These findings support safe and effective transition strategies between cangrelor and ticagrelor.